NEW YORK ─ Harvard's Wyss Institute for Biologically Inspired Engineering announced Monday that it has licensed a low-cost, affinity-based electrochemical sensing platform, called eRapid, to Sydney-based iQ Group Global for COVID-19 diagnostic testing applications.
iQ Group Global, a consortium of Australian companies, will integrate the biomarker detection technology with its transistor technology to enable specific and sensitive SARS-CoV-2 testing, Wyss Institute said.
Financial and other terms of the agreement were not disclosed.